A Multiomics Study Based on the Dynamic Evolution of Endometrial Carcinogenesis

Not yet recruiting

• Conditions: the Dynamic Evolution of Endometrial Carcinogenesis; Multiomics Analysis

• Registration Number: NCT06007300
• Lead Sponsor: RenJi Hospital

Brief Summary

The goal of this observational study is to draw the characteristic maps of imaging omics, genomics, transcriptome, proteomics, pathological omics, metabolomics, etc. of the dynamic evolution of endometrial carcinogenesis in 100 patients with normal endometrium, 100 patients with atypical endometrial hyperplasia, and 100 patients with endometrial cancer; and then to explore the underlying molecular mechanism, and establish the database system for the dynamic evolution of endometrial carcinogenesis.

Detailed Description

Not available

Study Timeline

• Status Verified: 2023-08
• Study Start: 2023-08
• Study First Submitted: 2023-08-09
• Study First Submitted QC: 2023-08-17
• Last Update Submitted: 2023-08-17
• Study First Posted: 2023-08-23
• Last Update Posted: 2023-08-23
• Primary Completion: 2026-06
• Study Completion: 2026-06

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: Female
• Target Recruitment: 300

Inclusion Criteria

• Pathological diagnosis: normal endometrium, atypical hyperplasia endometrium, or endometrial cancer;
• Obtain pathological results after undergoing hysteroscopic surgery or hysterectomy;
• The patient voluntarily participated in this research project with good compliance and was able to complete the enrollment according to the experimental requirements;
• Sign the informed consent form and consent to the collection and use of their data, and consent to genomics, transcriptome and other tests.

Exclusion Criteria

• Patients with malignant tumors in other parts of the body;
• Suffering from uncontrollable neurological diseases, psychiatric diseases, or psychiatric disorders;
• Poor compliance and inability to cooperate and describe treatment responders.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Differences in the expression of these mutant genes among the three groups of participants as assessed by SAS® 9.4	January 2026 to June 2026
The mutant genes of participants and their expression as assessed by gene sequencing, RNA sequencing and mass spectrometry analysis	August 2023 to June 2026